Open Access
ARTICLE
Injection of botulinum toxin type A in the urethral sphincter to treat lower urinary tract dysfunction: a review of indications, techniques and results
Department of Urology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada
Address correspondence to Dr. Jacques Corcos, Department
of Urology, Jewish General Hospital, 3755 Cote-SteCatherine, Montreal, Quebec, H3T 1E2
Canadian Journal of Urology 2006, 13(2), 3027-3033.
Abstract
The first application of botulinum toxin type A (BTA) in urology was its injection into the urinary sphincter to treat neurogenic detrusor-sphincter dyssynergia (DSD) in quadriplegic men. Since that first report in the eighties, the results of focal BTA injections into the sphincter, the bladder wall and lately into the prostate, have raised the interest of the urology community in this promising new therapeutic modality. An evidence-based review is presented of current indications, techniques and outcome of BTA injections into the urethral sphincter.Keywords
Cite This Article
Copyright © 2006 The Author(s). Published by Tech Science Press.This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Submit a Paper
Propose a Special lssue
Download PDF
Downloads
Citation Tools